Article Text

Download PDFPDF
25 Paigen diet-fed Apolipoprotein E knock-out mice develop severe pulmonary hypertension in an interleukin-1 dependent manner
  1. A Lawrie,
  2. A G Hameed,
  3. J Chamberlain,
  4. N Arnold,
  5. D C Crossman,
  6. S E Francis
  1. Department of Cardiovascular Science, Faculty of Medicine, Dentistry & Health, University of Sheffield Medical School, Sheffield, UK


Pulmonary arterial hypertension (PAH) is a life threatening condition with high morbidity and mortality. Inflammatory mechanisms are proposed to play a significant role in disease progression. Previous studies have described mild PAH in western-diet fed Apolipoprotein E knock out mice (ApoE−/−). Our group has previously reported that ApoE−/− mice fed the Paigen diet develop 40% more atherosclerosis than littermates fed the western diet, and that treatment with IL-1 receptor antagonist (IL-1Ra) reduced atherosclerosis. We subsequently hypothesised that ApoE−/− fed the Paigen diet would develop a more severe pulmonary hypertension phenotype than previously reported with the western diet, and that treatment with IL-1Ra would be able to reduce this phenotype. ApoE−/− mice fed the Paigen diet for 8 weeks developed significantly increased right ventricular systolic pressure compared to chow-fed littermates mean (50 vs 23 mm Hg, n=7 p<0.01). Immunohistological analysis of the lungs revealed evidence of a severe pulmonary vasculopathy, including heavily muscularised, and obliterative lesions in the small resistance pulmonary arteries (<50 μm) in Paigen diet-fed ApoE−/− mice. The media/CSA ratio of the small (<50 μm) and medium-sized pulmonary arteries (51–100 μm) was significantly increased in the Paigen diet-fed ApoE−/− mice compared to chow-fed controls. To test whether IL-1Ra could reduce this phenotype Paigen-fed ApoE−/− mice were treated with IL-1Ra or placebo for 4 weeks via a subcutaneous osmotic mini pump, following an initial 4 weeks on diet. ApoE−/− mice treated with IL-1Ra had significantly reduced RVSP (23 mm Hg) and pulmonary vascular remodelling (55%) compared to placebo treated controls. These data suggest that IL-1Ra may have beneficial effects in treating PAH.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.